New Pap Technologies Pap smear screening under scrutiny since late’80s

Slides:



Advertisements
Similar presentations
Clinical pathology: SEROMARKER FOR TB
Advertisements

NICE Guidance October 2003: NICE recommends that LBC is used as
The Impact of Gynecologic Pathology Diagnostic Errors on Patient Care Dana Marie Grzybicki MD, PhD Colleen M. Vrbin, BA Danielle Pirain, BS Stephen S.
Cervical Cancer and Vaccines
How to do cervical pap smear
Detection of human telomerase gene (TERC) amplification in cervical neoplasia: A retrospective study of 79 patients Pap smear slides Renarta Crookes Sheffield.
Hand-out associated with part I of the January Workload Webinar “Workload Issues for Computer-Aided Cytology Devices” ASCT Educational Webinar January.
Feature Screening Concept: A greedy feature selection method. Rank features and discard those whose ranking criterions are below the threshold. Problem:
1 ASCO 2004 Tumor Biology & Human Genetics Pap test and a new biomarker- based technology for enhancing the visibility of abnormal cells N.S. Markovic,
Cervical cancer screening in Estonia: present situation Piret Veerus Department of Epidemiology and Biostatistics National Institute for Health Development.
1 Historical overview of FDA regulation of digital pathology imaging applications: the safety and effectiveness issues Tremel A. Faison, MS, RAC, SCT(ASCP)
04/05/20041 Liquid Based Cytology Workshop. 04/05/20042 Programme content Session 1 : Overview of the cervical screening programme & why LBC has been.
Cytopathology: Technique and Interpretation
(Medical) Diagnostic Testing. The situation Patient presents with symptoms, and is suspected of having some disease. Patient either has the disease or.
The Role of the Cytology Laboratory
Screening Tests for Brest & Cervical Cancer
Basic Statistics in Clinical Research Slides created from article by Augustine Onyeaghala (MSc, PhD, PGDQA, PGDCR, MSQA,
Circulating tumor cells (CTCs) in blood of breast cancer patients: Cytological detection and technical characterization Enrica Bresaola, Mara Jo Miller,
Screening for Cervical Cancer by Visual Inspection Techniques Dr Aruna Batra VMMC & SJH.
52 Shrivenham Hundred Business Park Watchfield, Oxfordshire, SN6 8TY. UK Innovators in Light Management Technology Advances in Automated.
Cervical Cancer Screening Recommendations 2012, FDA Panel 2014.
SoftPAP® A Novel Collection Device for Cervical Cytology.
Mother and Child Health: Research Methods G.J.Ebrahim Editor Journal of Tropical Pediatrics, Oxford University Press.
1 Module ON-SITE SUPERVISION OVERVIEW. 2 Content Overview What is on-site supervision? Advantages and disadvantages of on-site supervision Organization.
The Future Control of Cervical Cancer Hazel Lewis Public Health Physician Wellington Cartwright Forum, 7 August 2015.
Screening for cervical cancer. Screening for cervical lesions Common disease Cancer is preventable Screening is easy MUST BE PERFORMED.
بسم الله الرحمن الرحيم.
INTRODUCTION TO CYTOLOGY.
The ThinPrep ® PapTest ™ PAUL SULTANA MLS Thursday, 22 October 2015.
Top Pap smear Questions. 1-When should Pap screening begin? Age 21 y/o,3yrs after first intercourse.
SLO: Apply previously learned technique to life cultures Ex. 3: Staining Techniques - Gram Stain, part 2 (Live Cultures)
1 BioSciCon, Inc. MarkPap® Platform Technology A guide to the Web Site
PA-303-B 11/02. Formerly known as AutoCyte  PREP SurePath  slides are intended as replacements for conventional gynecologic Pap smears.
ARCHAEOLOGY An Introduction. What is archaeology? Turn to the person sitting beside you and discuss what you believe archaeology is. Turn to the person.
Washington D.C., USA, July 2012www.aids2012.org Implementing Xpert ® MTB/RIF in Rural Zimbabwe Impact on diagnosis of smear-negative TB and time-
Introduction to data analysis: Case studies with iSIKHNAS data Day 1 1/ 69.
Introduction to Hypothesis Testing
Cytologic Findings in Type 2 Cervical Carcinomas: Some Cervical Carcinomas are more Difficult to Prevent with Screening R. Marshall Austin MD,PhD Magee-Womens.
National Laboratory Service Data Interpretation and Reporting David Johns.
AUSTRALIA INDONESIA PARTNERSHIP FOR EMERGING INFECTIOUS DISEASES Introduction to data analysis: Case studies with iSIKHNAS data Day 1 1/ 69.
Results of the HTA Adequacy Study JHF Smith Royal Hallamshire Hospital, Sheffield BAC Scientific Meeting 2013.
Liquid based cytology Liquid based Cytology.
What is a Pap smear? A Pap smear is a test your doctor does to check for signs of cancer of the cervix. The cervix is part of your uterus (womb). During.
WACCPP rolling PowerPoint. INSTRUCTIONS  This PowerPoint presentation has been designed for use as a rolling backdrop at presentations or events  Before.
Organisms, Behaviour and Health.  Training outcomes:  To compare a lesson teaching the concept of cells to a year 7 class with and without the use of.
Cytopathology Feb
Morphologic Pap Test Findings in HPV Negative Women Age 30 Years and Older: What Information Will Be Lost with HPV Only Primary Screening? Brooke Henninger,
Medical Diagnostic Center- L.E.M
A. Cervical cytology collection devices: (1) Plastic spatula
Quality issues in monitoring diagnostic and treatment performance Dr
Tremel A. Faison, MS, RAC, SCT(ASCP) FDA/CDRH/OIVD/DIHD
Tremel A. Faison, MS, RAC, SCT(ASCP) FDA/CDRH/OIVD/DIHD
Background and Rationale for the development of the Primary Health Care (PHC) Laboratory Toolkit
Sample Presentation. Slide 1 Info Slide 2 Info.
What Are Preservatives And Additives.
Embry Womens Health
Department of Pathology
کنترل کيفی در سيتولوژی سرويکوواژينال
Complete the following slides to get credit
MarkPap® TECHNOLOGY Focal Points BioSciCon, Inc. 12/31/2018.
Insured all year Total (%) Number (in millions) Uninsured anytime (%)
EUROPEAN UNION COMMUNITY REFERENCE LABORATORIES
The experience of Cervical Cancer
Task Force on Cervical Cancer Screening in Estonia
C.2.10 Sample Questions.
C.2.8 Sample Questions.
C.2.8 Sample Questions.
Modern cervical cancer screening
Cervical Screening Programme
Types of Errors And Error Analysis.
Presentation transcript:

New Pap Technologies Pap smear screening under scrutiny since late’80s Introduced in ’50s Little change since its introduction Powerful public health measure Morbidity and mortality remain high screening under scrutiny since late’80s Misdiagnosis –false negatives Quality Control

Sources of False Negatives Sampling/preparation errors Cells not collected on collecting device Collected cells not transferred to slide Poor preservation Screening errors Abnormal cells present or missed Interpretive errors

ThinPrep Pap test/ Liquid based cytology Pap Smear Majority of cells not captured Non-representative transfer of cells Clumping and overlapping of cells Obscuring material ThinPrep Majority of sample is collected Randomised representative transfer of cells Even distribution of cells Minimises obscuring material

ThinPrep processing Samples prepared under laboratory conditions Automated capacity Convenient Reproducible